BUTITTA CYNTHIA M 4

What Happened

• Cynthia M. Butitta, a director of UroGen Pharma Ltd. (URGN), received awards on 2026-06-22 consisting of: 10,000 underlying shares from a stock option grant and 8,000 restricted stock units (RSUs). Both awards were recorded at $0.00 per share (no cash purchase); total immediate cash outlay = $0. These are grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely filing, within the two-business-day requirement).
• Price: $0.00 per share for both entries (award/grant).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnotes of note:
  • F1: The 10,000-option award vests in equal quarterly installments over one year, subject to continuous service under the 2017 Equity Incentive Plan.
  • F2: Each RSU represents a contingent right to receive one ordinary share.
  • F3: The 8,000 RSUs vest in equal quarterly installments over one year, subject to continuous service.
• Filing timeliness: the Form 4 was filed two days after the transaction date, which is within standard timing rules.

Context

• These were grants of equity compensation (one stock option award and one RSU award). No exercise or sale occurred; the awards will vest over the coming year if the director remains in service. Such awards compensate and retain insiders and are not the same as an outright market purchase that might signal a direct bullish bet.